




# Rad Path: Liver Masses

LEIGH CASADABAN, MD  
RADIOLOGY

DAVID PAPKE, MD  
PATHOLOGY

# Role of Contrast on CT

- ▶ IV contrast distinguishes parenchyma from mass
  - ▶ Parenchyma enhances on portal venous phase (PVP)
  - ▶ Tumors enhance on arterial phase



# Role of Contrast on CT


- ▶ Hypervascular tumors are best seen on late arterial phase (35 sec)
- ▶ Hypovascular tumors are best seen on PVP (75 sec)
- ▶ Delayed/equilibrium phase imaging (3-5 min):
  - ▶ Tumor washout (HCC)
  - ▶ Retention in capsules (fibrous tissue) or scarring (FNH, cholangiocarcinoma)

# ACR: Indeterminate lesion on CT

Radiologic Procedure	Rating	Comments	RRL*
MRI abdomen without and with IV contrast	8	Consider this procedure if CT characterization is incomplete.	O
MRI abdomen without IV contrast	7	Consider this procedure if MRI with gadolinium is contraindicated. A noncontrast-enhanced MRI is superior to a noncontrast-enhanced CT.	O
US abdomen	5	Consider this procedure to diagnose a cyst versus solid lesion and to guide a percutaneous biopsy.	O
Percutaneous image-guided biopsy liver	5	Consider this procedure if imaging findings are atypical, inconclusive, or suspicious for malignancy after doing contrast-enhanced CT or MRI.	Varies
Tc-99m sulfur colloid scan liver	3	Consider this procedure to evaluate for FNH if GFR precludes CT or MRI contrast agents.	☼☼☼
Tc-99m RBC scan liver	3	Consider this procedure if a hemangioma is suspected and if GFR precludes CT or MRI contrast agents.	☼☼☼
In-111 somatostatin receptor scintigraphy	3	This procedure is not appropriate unless there is a known or suspected neuroendocrine tumor.	☼☼☼☼
FDG-PET/CT whole body	3	This procedure is not appropriate unless there is a known malignancy.	☼☼☼☼
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>



# ACR White Paper 2010



# ACR Liver Metastases: Initial Imaging

## **Variant 1:**


**Suspected liver metastases. Initial imaging test following detection of primary tumor.**

Radiologic Procedure	Rating	Comments	RRL*
CT abdomen with IV contrast	9		☼ ☼ ☼
MRI abdomen without and with IV contrast	8		○
CT abdomen without and with IV contrast	5		☼ ☼ ☼ ☼
MRI abdomen without IV contrast	5		○
FDG-PET/CT skull base to mid-thigh	5		☼ ☼ ☼ ☼
In-111 somatostatin receptor scintigraphy	5		☼ ☼ ☼ ☼
US abdomen	4		○
CT abdomen without IV contrast	4		☼ ☼ ☼
<b><u>Rating Scale:</u> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</b>			<b>*Relative Radiation Level</b>


# Case 1

- ▶ 77 YOM with fatigue and iron deficiency anemia for 1 year
- ▶ Completely normal CT abdomen/pelvis 3 years prior
- ▶ AFP 2.2 (ref <7.9)


Pre






Arterial



Equilibrium














MRN: 34234336

BS-16-65482


(liver biopsy)

















#### A. LIVER MASS BIOPSY:

Cirrhotic liver parenchyma with extensive multi-acinar collapse and florid ductular proliferation with focal atypia, SEE NOTE


NOTE: Although some morphological atypia is seen within foci of ductular proliferation, diagnostic features for hepatocellular carcinoma or cholangiocarcinoma are not present in these biopsies.


A reticulin stain and immunostains for SMAD4 (intact), p53, MIB-1, Glypican-3, glutamine synthetase, CD34, CK7 and beta-catenin were also performed for final diagnosis.




MRN: 34234336  
BS-16-65482  
(adrenal biopsy)












# Arginase-1






SPECIMEN DESIGNATED "LEFT ADRENAL MASS, CORE BIOPSY":

Morphologically and immunohistochemically consistent with HEPATOCELLULAR CARCINOMA, moderately differentiated by WHO grading system (Edmonson/Steiner grade 3), with necrosis, present as detached fragments together with background adrenal parenchyma and inflamed fibrous tissue. See note.

Note: Focal green/brown pigment is noted in association with tumor cells (nonspecific, but in context possibly bile pigment). Hyaline cytoplasmic globules are also noted. The architecture of the microfragments is focally suggestive of a thick trabecular growth pattern (best seen on H&E; reticulin stain also examined). Immunostains show that the tumor cells are positive for ARG-1 (cytoplasmic and nuclear) and TTF1 (multifocal, cytoplasmic) and negative for SOX10. Immunostains for SF1 and Melan-A/A103 highlight the adrenal parenchyma, but the tumor cells are negative for these markers.



Which is NOT a macroscopic growth pattern of HCC?

- ▶ A) Nodular
- ▶ B) Follicular
- ▶ C) Massive
- ▶ D) Infiltrative

# Hepatocellular Carcinoma

- ▶ HCC is the 2<sup>nd</sup> leading cause of cancer death in men, and 6<sup>th</sup> in women worldwide
- ▶ Typically large with mosaic pattern
- ▶ Capsule, hemorrhage, necrosis and fat evolution
- ▶ Most are hypervascular; only 10% are hypovascular



# Infiltrative HCC

- ▶ Infiltrative (cirrhotomimetic-type) HCC accounts for 7-20%, commonly in HBV patients, and has substantially worse prognosis
- ▶ Least likely to correlate with AFP levels
- ▶ Imaging features of infiltrative HCC are different:
  - ▶ Minimal, patchy or miliary arterial enhancement
  - ▶ Hypointense or reticular on venous phase
  - ▶ Washout is less frequent, and irregular or heterogeneous

# Metastases

TABLE 8. Sites and Frequencies of Metastases (225 Cases)

Organ and tissue	No. of cases	Relative frequency
Mainly hematogenous	126 (56.0%)	87.5%
Lung	116 (51.6%)	80.6%
Adrenal	19 (8.4%)	
Bone	12 (5.8%)	
Pancreas	7 (3.1%)	
Kidney	5 (2.2%)	
Thyroid	2 (0.8%)	
Meninx	2 (5.4%)*	
Heart	2 (0.8%)	
Brain	1 (2.7%)*	
Mainly lymphogenous (lymph nodes)	60 (26.7%)	41.7%
Hilar	33 (14.7%)	22.9%
Head of pancreas	24 (10.7%)	16.7%
Around aorta	18 (8.0%)	
Retroperitoneum	13 (5.8%)	
Around stomach	12 (5.3%)	
Mediastinum	11 (4.9%)	
Around trachea	11 (4.9%)	
Around carina	9 (4.0%)	
Neck	7 (3.1%)	
Virchow	5 (2.2%)	
Inguinal	1 (0.4%)	
Mainly infiltrating and disseminating	49 (21.8%)	34.0%
Diaphragm	23 (10.2%)	16.0%
Douglas' pouch	14 (6.2%)	
Gallbladder	13 (5.8%)	
Stomach, intestine	9 (5.8%)	
Peritoneum	9 (5.8%)	
Pancreas surface	8 (3.6%)	
Heart	3 (1.3%)	
Esophagus	1 (0.4%)	
Ovary	1 (0.4%)	
Total	225 (100%)	144 (100%)

# LI-RADS is used for:


- ▶ A) Any focal liver mass
- ▶ B) Known extra-hepatic primary
- ▶ C) Only cirrhotic/Hepatitis patients
- ▶ D) Treated HCC



# LI-RADS

Liver Imaging Reporting and Data System (LI-RADS)

LR-1	Definitely Benign
LR-2	Probably Benign
LR-3	Intermediate probability for HCC
LR-4	Probably HCC
LR-5	Definitely HCC
LR-5V	Definitely HCC with Tumor in Vein
LR-M	Probable malignancy, not specific for HCC
LR-Treated	Treated Observation



# Case 2

- ▶ 55 YOF with 3-4 years of pruritus and elevated LFTs
- ▶ AFP = 1.7
- ▶ Normal mammogram and colonoscopy


Arterial



8 min Delay




**T1 In phase**




**T1 Out of phase**




**Arterial**



**PVP**



**5 min Delay**









MRN: 05844824

BS-14-44976


(resection only,  
biopsy unavailable)














# IHC

- Beta-catenin: negative (HCC positive)
- Glutamine synthetase: perivascular (HCC diffusely positive)
- Glypican-3 negative (HCC positive)



A. LIVER MASS, CORE BIOPSIES:

BENIGN HEPATOCELLULAR PROLIFERATION, see NOTE.

B. LIVER PARENCHYMA, CORE BIOPSIES:

Fragments of BENIGN HEPATOCELLULAR PROLIFERATION, see NOTE.

Non-neoplastic liver parenchyma with focal mild steatosis.

No fibrosis.

No iron.

NOTE: The findings are most consistent with adenoma, and the radiologic features of multiple smaller nodules with a similar enhancement pattern (as well as the presence of lesional tissue in both the mass and parenchymal biopsies) raises the possibility of adenomatosis. Histologic features of hepatocellular carcinoma are not seen. Clinical correlation is needed.

B-catenin, glypican-3 and glutamine synthetase immunostains examined for the final diagnosis (part A). Iron, trichrome, and reticulin stains were examined for the diagnosis (part B).



# What is the average size of a hepatic adenoma?

- ▶ A) <1 cm
- ▶ B) 1-8 cm
- ▶ C) 8-15 cm
- ▶ D) 15-25 cm



# Hepatic Adenoma

- ▶ Sheets of hepatocytes without bile ducts or portal areas
- ▶ Prone to necrosis and hemorrhage, lacks of central vascular supply
- ▶ Hypervascular but without neoplastic neovascularity fast wash-out
- ▶ Well-defined contour with subcapsular feeding arteries
- ▶ Consider in patients on oral contraceptives, anabolic steroids, or history of glycogen storage disease
- ▶ Surgical resection is recommended for >5cm, given risk of malignant transformation
- ▶ Biopsy is not recommended due to misdiagnosis and hemorrhage

# Thin fibrous pseudocapsule - 30%

- ▶ Less arterial enhancement
- ▶ Even hypodense on portal venous phase because fibrous tissue enhances slowly
- ▶ Best seen on delayed phase as relatively hypodense
- ▶ DDx: Adenoma, HCC, cystadenoma or cystadenocarcinoma
- ▶ HCC is most common

# 10% of Adenomas Contain Fat

**Table 1**  
**Liver Lesions Containing Macroscopic Fat**


Type of Lesion	Lesions Containing Only Fat	Lesions Containing Fat and Soft Tissue
Benign	Lipoma Xanthoma (Langerhans cell histiocytosis) Postoperative packing material (omentum)	Adenoma Hepatic adrenal rest tumor Angiomyolipoma Teratoma
Malignant	Primary liposarcoma Metastatic liposarcoma	Hepatocellular carcinoma Metastases Primary liposarcoma Metastatic liposarcoma

# Case 3

- ▶ 64 YOF presenting to the ED with epigastric discomfort
- ▶ History of brain meningioma, bilateral mastectomies and oophorectomy



# Case 3







MRN: 02526671

BS-16-01572

(liver biopsy)











## LIVER, CORE NEEDLE BIOPSY FOR A MASS:

METASTATIC CARCINOMA to the liver, consistent with spread from a breast primary carcinoma (see note).

Immunoperoxidase studies were performed at BWH on formalin fixed tissue with the following results for metastatic carcinoma (block A1):

ESTROGEN RECEPTOR	POSITIVE (>95% moderate to strong)
PROGESTERONE RECEPTOR	NEGATIVE (0%)
HER2/NEU (C-ERB-B2)	NEGATIVE (0)

External controls are evaluated and show appropriate immunoreactivity.

NOTE: The patient has a history of left breast DCIS and LCIS in 1999, and is status post bilateral mastectomies. She was found to have neck metastasis in 2012, most consistent with a breast primary, which was estrogen receptor positive, progesterone receptor negative and HER2 negative.



# Fibrous liver mets that can cause capsular retraction include all EXCEPT?

- ▶ A) Lung
- ▶ B) Breast
- ▶ C) Neuroendocrine
- ▶ D) RCC
- ▶ E) Colon

# Retraction of liver capsule

- ▶ Tumors with infiltrative growth and dense fibrous tissue that do not cause mass effect
- ▶ Treated breast mets can cause “pseudo-cirrhosis” appearance
- ▶ DDx: infiltrative cholangiocarcinoma, focal atrophy due to biliary or portal venous obstruction, sclerosed hemangioma, confluent hepatic fibrosis (cirrhosis)




# Case 4


- ▶ 52 YOF underwent colonoscopy that found an unusual indentation felt to represent extrinsic compression from the liver



# Case 4

T2




T2







**Pre**



**60 sec**



**5 min**








MRN: 31615537

BS-15-60008


(liver resection)





























C. COMMON DUCT LYMPH NODE (INCLUDING FSC):  
METASTATIC ADENOCARCINOMA involving lymph node.

D. RIGHT LIVER SEGMENT 5, 6, 7, 8 WITH GALLBLADDER (INCLUDING FSD):  
INTRAHEPATIC CHOLANGIOCARCINOMA, MODERATELY DIFFERENTIATED (5.6 cm).  
Carcinoma is present as a unifocal cystic mass.  
The right hepatic duct margin is negative for carcinoma.  
The venous resection margins are negative for carcinoma.  
Invasive carcinoma is 0.4 cm from the hepatic parenchymal resection margin and 1.5 cm from the right hepatic duct resection margin.  
Carcinoma does not perforate the hepatic capsule.  
Extensive lymphovascular invasion is present in adjacent liver parenchyma.  
Macroscopic/microscopic venous invasion is not identified.  
Perineural invasion is not identified.  
Non-neoplastic hepatic parenchyma within normal limits.  
1+ stainable iron.  
Iron, trichrome, and reticulin stains were examined for the diagnosis.  
Gallbladder with no significant pathologic change.  
AJCC Classification (7th edition): pT1 N1.

# What is the most common location for cholangiocarcinoma (CCA)?

- ▶ A) Intrahepatic (iCCA)
- ▶ B) Perihilar (pCCA)
- ▶ C) Distal (dCCA)
- ▶ D) All are equal




# Cholangiocarcinoma

- ▶ Arise from cholangiocytes anywhere from the terminal ductules to the ampulla of Vater
- ▶ 90% adenocarcinoma, 10% squamous cell carcinoma
- ▶ Produces variable amounts of mucin, that mostly remains within the tumor
- ▶ Papillary, mucin-producing, or cystic type
- ▶ Lifetime risk with primary sclerosing cholangitis (PSC) is 5-10%
- ▶ Bile duct disorders and hepatitis C infection increase risk



# Intraductal Papillary Biliary Neoplasm (IPNB)

- ▶ Similar to IPMN of the pancreas
- ▶ Variant of bile duct carcinoma and characterized by intraductal growth
- ▶ Precursor for invasive carcinoma
- ▶ Difficult to distinguish from mucinous cystic neoplasms on imaging



# Case 5


- ▶ 66 YOF with nausea, vomiting and dull achy right flank pain after striking herself against a picture frame while working as a cashier
- ▶ Denies fever, vomiting, nausea
- ▶ History of HTN, HL, and “Hepatitis-D”
- ▶ Elevated creatinine and LFTs


# Case 5






# Case 5






MRN: 28402014  
BC-13-23535  
(liver fine needle  
aspiration)
























## **FINAL CYTOLOGIC INTERPRETATION**

INTERPRETATION:

POSITIVE FOR MALIGNANT CELLS.

DIAGNOSIS:

Morphologically consistent with pleomorphic liposarcoma. See note.

NOTES AND RECOMMENDATIONS:

NOTE: On smears and cell block sections, most cells in this pleomorphic neoplasm show intracytoplasmic lipid-filled vacuoles (lipid best seen on direct smears prior to coverslipping). Many morphologically classic lipoblasts are present. Necrosis is noted, and mitoses number up to 20 per 10 high power fields. No recognizable epithelial structures are present. Immunostains show that the tumor cells are positive for CD10 and negative for S100, HMB45, MART1, CD34, and SMA, and show only weak/focal staining for PAX8, MDM2, and CDK4. Attempted cytogenetic analysis is in progress and will be reported separately.

Pleomorphic liposarcoma in the liver usually represents metastasis. In the clinical context of a uterine mass with presumed fatty component, the liver tumor likely represents metastasis of a (pleomorphic) liposarcomatous component of a malignant mixed müllerian tumor. Clinical correlation is essential. Case reviewed at Cytology Staff Conference and with Dr. C. Fletcher.

# Which is NOT one of the four types of liposarcoma?

- ▶ A) Moderately differentiated liposarcoma
- ▶ B) Well-differentiated liposarcoma
- ▶ C) Pleomorphic liposarcoma
- ▶ D) Myxoid/round cell liposarcoma
- ▶ E) Dedifferentiated liposarcoma



# Pleomorphic liposarcoma

- ▶ Rarest type of liposarcoma (5-10%)
- ▶ High grade in nature
- ▶ Primary is often in the extremities (76%) or retroperitoneum (9%)
- ▶ Rarely see metastases to liver
- ▶ Patients over 50

# Liver Lesions with Macroscopic Fat

**Table 1**  
**Liver Lesions Containing Macroscopic Fat**


Type of Lesion	Lesions Containing Only Fat	Lesions Containing Fat and Soft Tissue
Benign	Lipoma Xanthoma (Langerhans cell histiocytosis) Postoperative packing material (omentum)	Adenoma Hepatic adrenal rest tumor Angiomyolipoma Teratoma
Malignant	Primary liposarcoma Metastatic liposarcoma	Hepatocellular carcinoma Metastases Primary liposarcoma Metastatic liposarcoma

# Case 6


- ▶ 53 YOF with incidental liver mass
- ▶ LFTs normal




T2




T1 Arterial




T1 PVP




In phase




Out of phase




**Pre**



**Arterial**




**Venous**





**10 min**






MRN: 29645264  
BS-16-42026  
(liver resection)

































# Desmin



HMB-45





C. RIGHT LIVER SEGMENTS 5,6,7,8 (INCLUDING FSC1, FSC2):

Epithelioid ANGIOMYOLIPOMA (16.0 cm) with scattered foci of extramedullary hematopoiesis.

Tumor present grossly at surgical resection margin

There are no overt features of malignancy.

Immunohistochemistry performed at BWH demonstrates the following staining profile in lesional cells:

Positive - SMA, Melan-A, MART-1, HMB45, Desmin (focal)

Negative - S-100

The immunohistochemical profile supports the above diagnosis.

NOTE: The gross specimen was reviewed intraoperatively and two separate sections were submitted from the main tumor mass and the grossly positive surgical resection margin. The tumor morphology was similar in both sections and no overt features of malignancy were identified.



# Angiomyolipomas are most associated with?

- ▶ A) Female gender
- ▶ B) Serum tumor markers
- ▶ C) Hepatitis infection
- ▶ D) Cirrhosis
- ▶ E) Age over 50

# Angiomyolipoma

- ▶ AKA PEComa – Perivascular epithelioid cell tumor
- ▶ Blood vessels (angiod), smooth muscle (myoid) and mature fat (lipoid) components
- ▶ Large early draining vein
- ▶ No vessel compression
- ▶ 6% association with tuberous sclerosis, less strong than for renal AMLs (20%)
- ▶ Fat content can vary from 10-95%.

# Liver Lesions with Macroscopic Fat

**Table 1**  
**Liver Lesions Containing Macroscopic Fat**

Type of  
Lesion

Lesions Containing Only Fat

Benign

Lipoma  
Xanthoma (Langerhans cell histiocytosis)  
Postoperative packing material  
(omentum)

Malignant

Primary liposarcoma  
Metastatic liposarcoma

Lesions Containing Fat  
and Soft Tissue

Adenoma  
Hepatic adrenal rest tumor  
Angiomyolipoma  
Teratoma  
Hepatocellular carcinoma  
Metastases  
Primary liposarcoma  
Metastatic liposarcoma



# Bibliography

- ▶ Banales, et al. Expert consensus document. Nature Reviews Gastroenterology and Hepatology. 2016; 13 (261-281)
- ▶ Berland, et al. Managing Incidental Findings on Abdominal CT: White paper of the ACR incidental Findings Committee. 2010; ACR 7(10)754-773.
- ▶ Chaib, et al. Hepatic Adenoma. Timing for Surgery. Hepato-gastroenterology. 2007; 54(1378-1384)
- ▶ Murphey et al. Imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation. AFIP Archives. 2005;25(5) 1371-1395
- ▶ Nakashima, et al. Pathology of hepatocellular carcinoma in Japan. Cancer 1983; 51(5) 863-877
- ▶ Oliver, et al. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Kidney International. 2010; 77(8) 669-80
- ▶ Prasad et al. Fat-containing lesions of the liver: radiology-pathology correlation. RadioGraphics 2005; 25(321-331)
- ▶ Razumilava et al. Classification, Diagnosis and Management of Cholangiocarcinoma. Clinical Gastroenterology and Hepatology. 2013;11(1)
- ▶ Tan, et al. Causes of Hepatic Capsular Retraction: A Pictorial Essay. Imaging Insights. 2016; 7(6) 831-840
- ▶ Zhu, et al. Myomatous hepatic angiomyolipoma: imaging findings in 14 cases with Radiological-Pathological correlation and review of literature. British Journal of Radiology. 2014; 87(1034)